1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
FEATURED COMPANIES
- Aurobindo Pharma Ltd.
- Bayer AG
- GlaxoSmithKline Plc
- Granules India Ltd.
- Mylan NV
- Novartis AG
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
Global West Nile Virus Therapeutics Market: About this market
The West Nile virus therapeutics market analysis considers sales from both neuroinvasive and non-neuroinvasive applications. Our analysis also considers the sales of West Nile virus therapeutics in Asia, Europe, North America, and ROW. In 2018, the neuroinvasive segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as occurrence of different symptoms will play a significant role in the neuroinvasive segment to maintain its market position. Also, our global West Nile virus therapeutics market report looks at factors such as communicable nature of the disease, availability of over-the-counter (OTC) therapeutics, and availability of diagnostic tests. However, programs to control mosquito breeding, lack of approved therapies, and asymptomatic nature of the disease may hamper the growth of the West Nile virus therapeutics industry over the forecast period.
Global West Nile Virus Therapeutics Market: Overview
Availability of over-the-counter therapeutics
West Nile Virus infection does not have a specific drug or vaccine that is approved or ideal for patients. However, the CDC recommends the treatment of associated symptoms using OTC analgesics. OTC drugs such as aspirin and ibuprofen are the most commonly used drugs, which patients use to self-medicate and treat their illness at home. The purchase of these drugs does not require a prescription from a doctor and are of low cost. These benefits boost patient adherence and will lead to the expansion of the global West Nile virus therapeutics market at a CAGR of over 2% during the forecast period.
Rising awareness
In the absence of vaccines for the prevention of West Nile Virus infection, the only ways of reducing the health burden of the infection are by creating awareness among people about the risk factors and symptoms and educating people about the treatment measures. The increasing mosquito population poses the ever-growing threat of mosquito-borne illnesses worldwide, which is likely to encourage fresh players to enter the market to meet the rising demand for preventive and curative measures for these illnesses and is thus, anticipated to have a positive impact on market growth.
Competitive Landscape
With the presence of several major players, the global West Nile virus therapeutics market is fairly fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading West Nile virus therapeutics manufacturers, that include Aurobindo Pharma Ltd., Bayer AG, GlaxoSmithKline Plc, Granules India Ltd., Johnson & Johnson Services Inc., Mylan NV, Novartis AG, Perrigo Co. Plc, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.
Also, the West Nile virus therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The West Nile virus therapeutics market analysis considers sales from both neuroinvasive and non-neuroinvasive applications. Our analysis also considers the sales of West Nile virus therapeutics in Asia, Europe, North America, and ROW. In 2018, the neuroinvasive segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as occurrence of different symptoms will play a significant role in the neuroinvasive segment to maintain its market position. Also, our global West Nile virus therapeutics market report looks at factors such as communicable nature of the disease, availability of over-the-counter (OTC) therapeutics, and availability of diagnostic tests. However, programs to control mosquito breeding, lack of approved therapies, and asymptomatic nature of the disease may hamper the growth of the West Nile virus therapeutics industry over the forecast period.
Global West Nile Virus Therapeutics Market: Overview
Availability of over-the-counter therapeutics
West Nile Virus infection does not have a specific drug or vaccine that is approved or ideal for patients. However, the CDC recommends the treatment of associated symptoms using OTC analgesics. OTC drugs such as aspirin and ibuprofen are the most commonly used drugs, which patients use to self-medicate and treat their illness at home. The purchase of these drugs does not require a prescription from a doctor and are of low cost. These benefits boost patient adherence and will lead to the expansion of the global West Nile virus therapeutics market at a CAGR of over 2% during the forecast period.
Rising awareness
In the absence of vaccines for the prevention of West Nile Virus infection, the only ways of reducing the health burden of the infection are by creating awareness among people about the risk factors and symptoms and educating people about the treatment measures. The increasing mosquito population poses the ever-growing threat of mosquito-borne illnesses worldwide, which is likely to encourage fresh players to enter the market to meet the rising demand for preventive and curative measures for these illnesses and is thus, anticipated to have a positive impact on market growth.
Competitive Landscape
With the presence of several major players, the global West Nile virus therapeutics market is fairly fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading West Nile virus therapeutics manufacturers, that include Aurobindo Pharma Ltd., Bayer AG, GlaxoSmithKline Plc, Granules India Ltd., Johnson & Johnson Services Inc., Mylan NV, Novartis AG, Perrigo Co. Plc, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.
Also, the West Nile virus therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Aurobindo Pharma Ltd.
- Bayer AG
- GlaxoSmithKline Plc
- Granules India Ltd.
- Mylan NV
- Novartis AG
PART 01: EXECUTIVE SUMMARYPART 07: CUSTOMER LANDSCAPEPART 09: DECISION FRAMEWORK
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY APPLICATION
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
List of Exhibits
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Aurobindo Pharma Ltd.
- Bayer AG
- GlaxoSmithKline Plc
- Granules India Ltd.
- Mylan NV
- Novartis AG
The following companies are recognised as the key players in the global West Nile virus therapeutics market: Aurobindo Pharma Ltd., Bayer AG, GlaxoSmithKline Plc, Granules India Ltd., Johnson & Johnson Services Inc., Mylan NV, Novartis AG, Perrigo Co. Plc, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the rising awareness.”
According to the report, one of the major drivers for this market is the availability of over-the-counter therapeutics.
Further, the report states that one of the major factors hindering the growth of this market is the programs to control mosquito breeding.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the rising awareness.”
According to the report, one of the major drivers for this market is the availability of over-the-counter therapeutics.
Further, the report states that one of the major factors hindering the growth of this market is the programs to control mosquito breeding.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- Aurobindo Pharma Ltd.
- Bayer AG
- GlaxoSmithKline Plc
- Granules India Ltd.
- Johnson & Johnson Services Inc.
- Mylan NV
- Novartis AG
- Perrigo Co. Plc
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown